Latest News-Venus Medtech (Hangzhou) Inc. Mediaroom_Page

Cardiovalve Submits CE File for Approval Following Successful TARGET Study Completion

Exciting Data on Cardiovalve Tricuspid Valve Replacement Device Presented at PCR London Valves 2025...

2025-11-17 17:00 790

Cardiovalve Submits CE File for Approval Following Successful TARGET Study Completion

Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement

The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 20...

2025-10-25 15:00 2548

Court Sides with Cardiovalve in Edwards patent spat

HANGZHOU, China, Aug. 5, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. ("Venus Medtech", Stock...

2025-08-05 20:00 1708

Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations

HONG KONG, April 22, 2025 /PRNewswire/ -- Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, herei...

2025-04-22 09:00 3723

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

HANGZHOU, China, Sept. 5, 2024 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus Medtech, 02500....

2024-09-05 16:56 2674

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.

HANGZHOU, China, June 14, 2024 /PRNewswire/ -- Venus Medtech (02500. HK), a leading provider of int...

2024-06-14 15:15 3406

Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.

Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval

HANGZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Venus Medtech (02500. HK), a leading provider of inte...

2024-02-05 21:00 3175

Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval

Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023

The company will be presenting its growing pipeline of superb technologies for treating all four he...

2023-11-20 07:09 2944

Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023

VenusP-Valve granted IDE approval for clinical trial, unveiling a new chapter for Chinese valve solutions globally

HANGZHOU, China, Aug. 7, 2023 /PRNewswire/ -- Recently, Venus Medtech (Hangzhou ) Inc. ("Venus Medte...

2023-08-07 08:20 3703

VenusP-Valve granted IDE approval for clinical trial, unveiling a new chapter for Chinese valve solutions globally

Confirmatory clinical trial of Liwen RF™ ablation system in China concluded

HANGZHOU, China, March 6, 2023 /PRNewswire/ -- On March 3, Venus Medtech ( Hangzhou) Inc. (Venus Med...

2023-03-06 07:29 3301

Confirmatory clinical trial of Liwen RF™ ablation system in China concluded

Venus Medtech to showcase its structural heart treatments at London Valves 2022

The company's growing number of solutions for structural heart disease will be presented at multipl...

2022-11-25 18:08 7840

Venus Medtech announces 2022 interim results: quality and efficiency improvement, profitability focus, rapid progress in global presence

HANGZHOU, China, Sept. 1, 2022 /PRNewswire/ -- On August 31, 2022, Venus Medtech (Hangzhou) Inc. (2...

2022-09-01 20:55 4690

Venus Medtech announces 2022 interim results: quality and efficiency improvement, profitability focus, rapid progress in global presence

Filling gap in market: VenusP-Valve™ approved by China's NMPA

HANGZHOU, China, July 13, 2022 /PRNewswire/ -- On July 11, 2022, VenusP-ValveTM , Venus Medtech's in...

2022-07-13 20:26 3349

Filling gap in market: VenusP-Valve™ approved by China's NMPA

First American Patient Treated with VenusP-Valve™ Under Compassionate Use

HANGZHOU, China, June 22, 2022 /PRNewswire/ -- VenusP-Valve™, an in-house developed novel medical d...

2022-06-22 18:02 2913

First American Patient Treated with VenusP-Valve™ Under Compassionate Use

VenusP-Valve(TM) obtains CE marking under MDR and debuts in Europe as China's first valve product

HANGZHOU, China, April 12, 2022 /PRNewswire/ -- On April 8th, 2022, VenusP-Valve TM, Venus Medtech's...

2022-04-12 09:20 1108

VenusP-Valve(TM) obtains CE marking under MDR and debuts in Europe as China's first valve product

Venus Medtech announces 2021 annual results: pacesetter in China and breakthrough-maker worldwide

HANGZHOU, China, April 1, 2022 /PRNewswire/ -- On March 31, 2022, Venus Medtech (Hangzhou) Inc. (25...

2022-04-01 10:34 2945

Venus Medtech announces 2021 annual results: pacesetter in China and breakthrough-maker worldwide

Venus Medtech appoints Shakeel Osman as Senior VP of Sales Europe to drive commercialization of TPVR system

HANGZHOU, China, March 18, 2022 /PRNewswire/ -- On March 18th, 2022, Venus Medtech (Hangzhou) Inc. ...

2022-03-18 20:02 4980

Venus Medtech appoints Shakeel Osman as Senior VP of Sales Europe to drive commercialization of TPVR system

Venus Medtech Concludes Acquisition of 100% Equity Interest in Cardiovalve

HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.H...

2022-01-26 14:28 5772

Venus Medtech Concludes Acquisition of 100% Equity Interest in Cardiovalve

Venus Medtech Acquires Cardiovalve to Optimize its Innovative Products Pipeline of Mitral and Tricuspid Valve Replacement

HANGZHOU, China, Dec. 8, 2021 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK...

2021-12-08 08:28 4525

Venus Medtech Appoints Professor Martin B. Leon as Global Principal Investigator of Its New-Generation RDN System

HANGZHOU, China, July 28, 2021 /PRNewswire/ -- On July 27, 2021, Venus Medtech ( Hangzhou) Inc. ("V...

2021-07-28 11:41 5492